Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Angiomax Generics Imminent After Court Rules Patents Are Invalid

This article was originally published in The Pink Sheet Daily

Executive Summary

Exactly when The Medicine Co.'s top seller will see competition isn't clear – highlighting industry concerns with FDA review times for ANDAs. Hospira and Sagent have tentative approval and several other firms have pending applications.

Advertisement

Related Content

Supreme Court And Patents: What’s Not Happening
Angiomax Generic From Hospira Might Launch At-Risk Launch In 2015

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS078705

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel